Drugs that directly kill the dormant cells or maintain them in a dormant state will likely provide long-term benefits for breast cancer patients 25, 39, 91-93, as supported by an NR2F1 agonist that suppresses metastasis by inducing cancer cell dormancy 26, 27. Here, NR2F1 is linked to breast carcinoma.